title: [The prophylaxis against post-liver-transplant hepatitis B re-infection].
abstract: OBJECTIVE
  To review the prophylaxis against post-liver transplantation hepatitis B reinfection with anti-hepatitis B immunoglobulin and nucleoside analogues.
  
  
  METHODS
  A bibliographic search was carried out using Pubmed, entering the following key words: hepatitis B and liver transplantation and (hepatitis B hyperimmune globulin and lamivudine and adefovir dipivoxil) up to June 2006. The initial search was filtered using the terms clinical trial, randomized clinical trial and review. The data contained in selected studies were reviewed.
  
  
  RESULTS
  A total of 53 works were found. Prophylaxis with anti-HB immunoglobulin and lamivudine is the best strategy for avoiding recurrence of the hepatitis B virus in patients undergoing hepatic transplants; achieving very low reinfection rates (0-10%) with follow up periods of between 1-5 years. There is a great degree of variability (dose, duration and method of HBIg administration) in the prophylactic protocols reviewed. The use of low doses of anti-HB immunoglobulin (administered intravenously followed by intramuscular administration, or administered intramuscularly from the anhepatic stage), and lamivudine in patients who receive transplants with a low risk of recurrence, shows prophylactic efficacy comparable to the use of high doses of anti-HB immunoglobulin. Furthermore, it implies a considerable reduction in costs.
  
  
  CONCLUSIONS
  The availability of suitably designed clinical trials is required to design a more cost-effective protocol and reduce variability.
authors: Servicio de Farmacia, Hospital Universitario Río Hortega, Valladolid. jpradal@sefh.es
authors: J
authors: J
authors: Prada Lobato
authors: S
authors: S
authors: Garrido López
authors: M A
authors: MA
authors: Catalá Pindado
authors: F
authors: F
authors: García Pajares
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D006509:Hepatitis B / Q000517:prevention & control* / Q000821:virology*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D016031:Liver Transplantation; D063065:Organophosphonates / Q000627:therapeutic use*; D011183:Postoperative Complications; D012008:Recurrence
chemical_list: D019380:Anti-HIV Agents; D007136:Immunoglobulins; D063065:Organophosphonates; D019259:Lamivudine; C053001:adefovir; D000225:Adenine; C045213:hepatitis B hyperimmune globulin